Harriet Belding Eldredge1, Albert Denittis, James B Duhadaway, Michael Chernick, Richard Metz, George C Prendergast. 1. Department of Radiation Oncology, Lankenau Medical Center, Wynnewood PA 19096 USA [H.E., A.D.]; Lankenau Institute for Medical Research, Wynnewood PA 19096 USA [A.D., J.B.D., M.C., G.C.P.]; New Link Genetics Corporation, Ames IA 50010 USA [R.M.]; and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia PA 19107 USA [H.B.E., G.C.P.].
Abstract
OBJECTIVE: The immune modulatory drug chloroquine (CQ) has been demonstrated to enhance survival following radiotherapy in patients with high-grade glioma in a clinical trial, but the efficacy in patients with brain metastases is unknown. We hypothesized that short-course CQ during whole brain radiotherapy (WBRT) would improve response to local therapy in patients with brain metastases. METHODS: A prospective, single-cohort study was performed combining WBRT with concurrent CQ to assess both the feasibility of and intracranial response to combined therapy in patients with brain metastases. Safety, tolerability and overall survival of this combination was also examined, along with allelic status of IDO2 (indoleamine 2,3-dioxygenase 2), an immune modulatory enzyme inhibited by chloroquine that may affect survival outcomes. CQ therapy (250 mg by mouth daily) was initiated 1 week before WBRT (37.5 Gy in 2.5 Gy daily fractions) in patients with newly diagnosed brain metastases from biopsy-proven, primary lung, breast or ovarian solid tumors (n=20). The primary endpoint was radiologic response 3 months after combined CQ and WBRT therapy. Secondary endpoints included toxicity and overall survival. Patients were stratified by IDO2 allelic status. RESULTS: After a median clinical follow up of 5 months (range, 0.5-31), 16 patients were evaluable for radiologic response which was complete response in two patients, partial response in 13 patients and stable disease in one patient. There were no treatment-related grade≥3 toxicities or treatment interruption due to toxicity. Median and mean overall survival was 5.7 and 8.9 months, respectively (range, 0.8-31). A trend toward increased overall survival was observed in patients with wild-type IDO2 compared to patients with heterozygous or homozygous configurations that ablate IDO2 enzyme activity (10.4 mos vs. 4.1 mos.; p=0.07). CONCLUSIONS: WBRT with concurrent, short-course CQ is well tolerated in patients with brain metastases. The high intracranial disease control rate warrants additional study.
OBJECTIVE: The immune modulatory drug chloroquine (CQ) has been demonstrated to enhance survival following radiotherapy in patients with high-grade glioma in a clinical trial, but the efficacy in patients with brain metastases is unknown. We hypothesized that short-course CQ during whole brain radiotherapy (WBRT) would improve response to local therapy in patients with brain metastases. METHODS: A prospective, single-cohort study was performed combining WBRT with concurrent CQ to assess both the feasibility of and intracranial response to combined therapy in patients with brain metastases. Safety, tolerability and overall survival of this combination was also examined, along with allelic status of IDO2 (indoleamine 2,3-dioxygenase 2), an immune modulatory enzyme inhibited by chloroquine that may affect survival outcomes. CQ therapy (250 mg by mouth daily) was initiated 1 week before WBRT (37.5 Gy in 2.5 Gy daily fractions) in patients with newly diagnosed brain metastases from biopsy-proven, primary lung, breast or ovarian solid tumors (n=20). The primary endpoint was radiologic response 3 months after combined CQ and WBRT therapy. Secondary endpoints included toxicity and overall survival. Patients were stratified by IDO2 allelic status. RESULTS: After a median clinical follow up of 5 months (range, 0.5-31), 16 patients were evaluable for radiologic response which was complete response in two patients, partial response in 13 patients and stable disease in one patient. There were no treatment-related grade≥3 toxicities or treatment interruption due to toxicity. Median and mean overall survival was 5.7 and 8.9 months, respectively (range, 0.8-31). A trend toward increased overall survival was observed in patients with wild-type IDO2 compared to patients with heterozygous or homozygous configurations that ablate IDO2 enzyme activity (10.4 mos vs. 4.1 mos.; p=0.07). CONCLUSIONS: WBRT with concurrent, short-course CQ is well tolerated in patients with brain metastases. The high intracranial disease control rate warrants additional study.
Authors: L M DeAngelis; V E Currie; J H Kim; G Krol; M A O'Hehir; F M Farag; C W Young; J B Posner Journal: J Neurooncol Date: 1989-09 Impact factor: 4.130
Authors: John H Suh; Baldassarre Stea; Abdenour Nabid; John J Kresl; André Fortin; Jean-Philippe Mercier; Neil Senzer; Eric L Chang; Adam P Boyd; Pablo J Cagnoni; Edward Shaw Journal: J Clin Oncol Date: 2005-11-28 Impact factor: 44.544
Authors: K J Murray; C Scott; H M Greenberg; B Emami; M Seider; N L Vora; C Olson; A Whitton; B Movsas; W Curran Journal: Int J Radiat Oncol Biol Phys Date: 1997-10-01 Impact factor: 7.038
Authors: D Antonadou; M Paraskevaidis; G Sarris; N Coliarakis; I Economou; P Karageorgis; N Throuvalas Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544
Authors: Rameshwar Patil; Alexander V Ljubimov; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Shawn Wagner; Satoshi Inoue; Bindu Konda; Arthur Rekechenetskiy; Alexandra Chesnokova; Janet L Markman; Vladimir A Ljubimov; Debiao Li; Ravi S Prasad; Keith L Black; Eggehard Holler; Julia Y Ljubimova Journal: ACS Nano Date: 2015-05-06 Impact factor: 15.881
Authors: Rameshwar Patil; Yosef Koronyo; Alexander V Ljubimov; Brenda Salumbides; Adam Mamelak; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Eggehard Holler; Pramod Butte; Maya Koronyo-Hamaoui; Julia Y Ljubimova; Keith L Black Journal: Bangk Med J Date: 2015-09
Authors: Angelika Bilger; Martin-Immanuel Bittner; Anca-L Grosu; Nicole Wiedenmann; Philipp T Meyer; Elke Firat; Gabriele Niedermann; Wolfgang A Weber; Dušan Milanović Journal: Strahlenther Onkol Date: 2014-06-14 Impact factor: 3.621
Authors: Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi Journal: Nat Rev Clin Oncol Date: 2021-11-24 Impact factor: 66.675
Authors: George C Prendergast; William J Malachowski; Arpita Mondal; Peggy Scherle; Alexander J Muller Journal: Int Rev Cell Mol Biol Date: 2017-09-21 Impact factor: 6.813
Authors: George C Prendergast; Richard Metz; Alexander J Muller; Lauren M F Merlo; Laura Mandik-Nayak Journal: Front Immunol Date: 2014-11-20 Impact factor: 7.561